Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Lipigon Pharmaceuticals

0,089

 

SEK

 

+1,14 %

Mindre end 1K følgere

LPGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+1,14%
-12,21%
+4,76%
+0,04%
-33,96%
-60,4%
-94,56%
-
-98,44%

Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are mainly treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and associated ancillary services are also offered. Lipigon Pharmaceuticals operates worldwide, with the largest presence in the Nordic market.

Læs mere
Markedsværdi
49,94 mio. SEK
Aktieomsætning
167,11 t SEK
Omsætning
10,29 mio.
EBIT %
-248,59 %
P/E
-
Udbytteafkast, %
-
Finanskalender
26.6
2025

Generalforsamling '25

26.8
2025

Delårsrapport Q2'25

20.11
2025

Delårsrapport Q3'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse27.5.2025, 06.36

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals
Pressemeddelelse31.3.2025, 06.25

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals
Selskabsmeddelelse20.3.2025, 11.15

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Pressemeddelelse21.11.2024, 13.12

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals
Selskabsmeddelelse21.11.2024, 09.00

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse18.9.2024, 10.51

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse28.8.2024, 05.43

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals
Selskabsmeddelelse9.7.2024, 12.00

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals
Pressemeddelelse20.6.2024, 06.30

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals
Pressemeddelelse29.5.2024, 06.03

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals
Pressemeddelelse15.5.2024, 06.28

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals
Selskabsmeddelelse14.5.2024, 05.53

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals
Pressemeddelelse23.2.2024, 07.08

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals
Pressemeddelelse7.2.2024, 15.00

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals
Pressemeddelelse12.12.2023, 09.11

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals
Pressemeddelelse28.11.2023, 07.13

Lipigon presents Lipisense® at Global CVCT Forum 2023

Lipigon Pharmaceuticals
Pressemeddelelse24.11.2023, 07.16

Redeye: Lipigon Q3 2023 - Stage set for Phase II

Lipigon Pharmaceuticals
Selskabsmeddelelse23.11.2023, 14.45

Lipigon reports a statistically confirmed reduction of target protein ANGPTL4 after repeated treatment with Lipisense®

Lipigon Pharmaceuticals
Selskabsmeddelelse13.11.2023, 07.28

Lipigon applies for clinical trial Phase II for Lipisense®

Lipigon Pharmaceuticals
Selskabsmeddelelse10.10.2023, 13.29

Lipigon secures US patent for treatment of cardiometabolic disease

Lipigon Pharmaceuticals
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team